Preclinical Blood-Brain Barrier Permeability Assessment Services
At Ace Therapeutics, we know that delivering drugs across the blood-brain barrier (BBB) is one of the most formidable challenges in Alzheimer's disease (AD) research. Our preclinical BBB permeability assessment services are designed to help you optimize CNS drug candidates by predicting and validating their ability to reach brain targets—whether you're targeting amyloid-beta plaques, tau pathology, or neuroinflammation.
The BBB's selective permeability protects the brain but often blocks promising therapeutics. Alzheimer's adds layers of complexity, including amyloid-driven neurovascular dysfunction and altered transporter expression. Failed BBB penetration accounts for over 30% of CNS drug attrition. Our solutions address this bottleneck by
A phased approach to balance speed and accuracy.
Human-relevant systems to mimic Alzheimer's pathophysiology.
Bridge the gap between in vitro data and biological relevance.
Accelerate candidate selection with predictive tools.
To address the multifaceted nature of Alzheimer's R&D, we deploy innovative platforms.
| Platform | Application |
| 3D bioprinted NVU models | Replicate Alzheimer's-specific neurovascular dysfunction for mechanistic studies. |
| LC-MS/MS quantification | Detect nanogram-level drug concentrations in brain homogenates and CSF. |
| BBB models | Study CLDN5/occludin tight junction proteins in AD contexts. |
| Species scaling algorithms | Predict human BBB penetration using rodent and non-rodent data. |
Navigating the BBB is more than a technical hurdle—it's a critical step toward defeating Alzheimer's. Let Ace Therapeutics be your guide in transforming promising candidates into brain-penetrant therapies. Contact us today to start optimizing your preclinical strategy.
How do you handle differences between human and rodent BBB biology
We perform parallel studies in species-specific models (e.g., human iPSC-derived BBB vs. mouse ISBP) and apply cross-species scaling algorithms to improve translational accuracy.
Can you test biologics like antibodies or gene therapies
Yes. Our platforms support large molecules, including antibody BBB shuttle screening and nanoparticle delivery systems.
What sample quantities are required for screening
Most assays require <1 mg for small molecules or 0.5 mg for biologics. Microsampling techniques minimize material use.
How long does a typical BBB permeability assessment take
Turnaround times range from 2 weeks (PAMPA-BBB) to 8 weeks (3D NVU model studies).
Do you provide guidance on structural optimization
Absolutely. Our team offers medicinal chemistry and biologics engineering support to enhance brain uptake while maintaining target engagement.
Our products and services are for research use only and can not be used for diagnostic or other purposes.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics is a specialized team of scientists and technical professionals committed to working closely with clients worldwide. We offer comprehensive preclinical testing solutions to support the development of novel therapies and medications across a range of disease areas.
Ace Therapeutics boasts a team of highly committed and skilled researchers dedicated to delivering innovative preclinical contract research solutions.
We provide tailored preclinical services designed to streamline your research process and advance promising concepts into actionable insights, ensuring efficient progress in drug development.